Melfalan Teva

Melphalan, the active ingredient in Melfalan Teva, is an alkylating agent presented as an injection solution for intravenous use. It is employed in the treatment of multiple myeloma, ovarian cancer, melanoma and neuroblastoma, targeting rapidly dividing malignant cells in adult patients. It is indicated for adult patients with these malignancies and is administered under the supervision of a qualified oncologist.

GNH USA supplies Melfalan Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution networks across multiple regions.

Melphalan is an alkylating chemotherapy agent used in the treatment of certain solid tumors and hematologic malignancies. - Multiple myeloma: prolongs survival and reduces disease burden. - Ovarian cancer: used in combination regimens to improve response rates. - Melanoma: employed in high‑dose protocols for advanced disease. - Neuroblastoma: part of intensive chemotherapy for high‑risk disease.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after infusion. - Myelosuppression: decreased white blood cells, red cells, and platelets. - Mucositis: inflammation of the oral and gastrointestinal mucosa. - Alopecia: temporary hair loss during treatment. - Fatigue: generalized weakness and reduced stamina.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related cancers. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: acute kidney injury in susceptible patients. - Cardiotoxicity: rare arrhythmias or myocardial depression.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for toxicity throughout treatment. - Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: check liver enzymes as melphalan is partially metabolized hepatically. - Hematologic status: perform complete blood counts before each cycle. - Pregnancy and lactation: avoid use; teratogenic potential is unknown. - Concomitant immunosuppression: assess infection risk and vaccinate appropriately. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Live vaccines: contraindicated due to immunosuppression. - Other alkylating agents: additive bone‑marrow toxicity. - Strong CYP inducers: may reduce plasma concentrations.

Moderate Interactions (Monitor Closely): - Antiemetics: may affect tolerability and dosing schedule. - Anticoagulants: increased bleeding risk; monitor coagulation parameters. - Nephrotoxic drugs: heightened risk of renal impairment; adjust dosing as needed.